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Abstract
Introduction: Compared to other activities of the testing process, the preanalytical phase is plagued by a lower degree of standardization, which 
makes it more vulnerable to errors. With the aim of providing guidelines and recommendations, the EFLM WG-PRE issued a survey across European 
medical laboratories, to gather information on local preanalytical practices. This is part one of two coherent articles, which covers all practices on 
monitoring preanalytical quality except haemolysis, icterus and lipemia (HIL).
Materials and methods: An online survey, containing 39 questions dealing with a broad spectrum of preanalytical issues, was disseminated to 
EFLM member countries. The survey included questions on willingness of laboratories to engage in preanalytical issues. 
Results: Overall, 1405 valid responses were received from 37 countries. 1265 (94%) responders declared to monitor preanalytical errors. Asse-
ssment, documentation and further use of this information varied widely among respondents and partially among countries. Many responders were 
interested in a preanalytical online platform, holding information on various aspects of the preanalytical phase (N = 1177; 87%), in a guideline for 
measurement and evaluation of preanalytical variables (N = 1235; 92%), and in preanalytical e-learning programs or webinars (N = 1125; 84%). 
Fewer responders were interested in, or already participating in, preanalytical EQA programs (N = 951; 71%). 
Conclusion: Although substantial heterogeneity was found across European laboratories on preanalytical phase monitoring, the interest in pre-
analytical issues was high. A large majority of participants indicated an interest in new guidelines regarding preanalytical variables and learning 
activities. This important data will be used by the WG-PRE for providing recommendations on the most critical issues.
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Introduction
The preanalytical phase of laboratory testing has 
long been known as the most vulnerable part of 
the total testing process, potentially leading to 
misidentifications, transportation/storage errors 
or erroneous results due to poor sample quality 
(haemolysis) or contamination, which can ulti-
mately lead to patient harm (1,2). This mostly aris-
es from many small risks eventually merging into 
an exponential risk of failure. More specifically, the 
fact that preanalytical processes predominantly 
take place outside the laboratory, makes it chal-
lenging to establish and enforce quality control 
measures comparable to those used as standard 
throughout the analytical processes. They also in-
volve many different stakeholders such as pa-
tients, clinicians, nurses and logistics personnel, 
thus the potential variables contributing to the de-
viation of test results are numerous (3). Despite 
these acknowledged facts, which influence the 
analytical outcome and potentially impair both 
patient diagnosis and management, relatively mi-
nor initiatives have been made to overcome this 
problem compared to the analytical phase. Prean-
alytical errors are widely monitored, but this prac-
tice is often limited to detecting haemolysis rates 
in a subset of samples received by the laboratory 
and noting the number of detected preanalytical 
errors related to received test tubes and test re-
quests. These investigations were again per-
formed in a very heterogeneous way, thus making 
it hard to perform reliable benchmarking (4-7). The 
reasons may include the lack of guidelines for 
health care staff to follow. However, even if guid-
ance is available on a specific preanalytical pro-
cess, adherence may often be limited as Simundic 
et al. demonstrated for venous blood collection 
(8). 
In the last decade, preanalytical issues have been 
addressed more extensively, with dedicated work-
ing groups being developed throughout Europe. 
In 2012, the European Federation of Clinical Chem-
istry and Laboratory Medicine (EFLM) established 
a Working Group for “Preanalytical Phase” (WG-
PRE). It began with five core members, evolving 
into a large and productive group, currently re-
sembling members from 17 European countries. 
The terms of reference for this WG include the pro-
vision of operating procedures and consensus 
guidelines based on current evidence in order to 
standardize and harmonize preanalytical process-
es, thus minimizing the risk of errors. 
The potential areas in the preanalytical process re-
quiring optimization/standardization emerge from 
all issues related to phlebotomy, transport or handl-
ing of preanalytically altered samples, among oth-
ers. In order to identify the areas for which guid-
ance is most urgently needed, a status of current 
practices on preanalytical topics is needed. There-
fore, the aim of this study was to survey European 
countries on questions regarding monitoring, doc-
umentation and evaluation of preanalytical errors, 
handling of haemolytic, lipemic or icteric samples, 
communication with clinicians and nurses about 
preanalytical topics, and the willingness/interest 
of laboratory professionals to focus more on these 
issues. 
Due to the large amount of data, the results and 
insights from this survey were split into two coher-
ent manuscripts. This first article presents the sur-
vey and subsequently displays and discusses if, 
and how, laboratories across Europe monitor the 
preanalytical phase and how data from this moni-
toring is currently used. Additionally, it focusses on 
the interest of participants in preanalytical issues 
and their willingness to actively engage in this 
topic. The second article presents and discusses 
the results of questions on haemolysis, lipemia 
and icterus monitoring (9). 
Materials and methods
A survey was developed by the WG-PRE, contain-
ing 39 questions, which covered general demo-
graphic information as well as specific aspects re-
garding the identification of preanalytical issues, 
haemolysis, icterus and lipemia, the evaluation of 
preanalytical measurements and the improve-
ment of respective processes using their outcomes 
along with standardization of preanalytical issues. 
All questions and respective answering options 
are shown in Supplemental Table 1. 
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Country Responders, N (%)
Albania 16 (1.2)
Austria 67 (5.0)
Belgium 63 (4.7)
Bosnia and Herzegovina 9 (0.7)
Bulgaria 12 (0.9)
Croatia 61 (4.5)
Cyprus 1 (0.1)
Czech Republic 60 (4.5)
Denmark 27 (2.0)
Estonia 8 (0.6)
Finland 21 (1.6)
France 194 (14)
Germany 55 (4.1)
Greece 7 (0.5)
Hungary 16 (1.2)
Ireland 18 (1.3)
Italy 64 (4.8)
Latvia 1 (0.1)
Lithuania 1 (0.1)
Luxembourg 3 (0.2)
Macedonia 21 (1.6)
Montenegro 7 (0.5)
Netherlands 83 (6.2)
Norway 63 (4.7)
Poland 3 (0.2)
Portugal 61 (4.5)
Romania 3 (0.2)
Russia 20 (1.5)
Serbia 54 (4.0)
Slovakia 12 (0.9)
Slovenia 23 (1.7)
Spain 120 (8.9)
Sweden 14 (1.0)
Switzerland 56 (4.2)
Turkey 26 (1.9)
United Kingdom (Great Britain) 75 (5.6)
Ukraine 2 (0.1)
Total 1347 (100)
Answers only by responders who were from EFLM member 
countries and did NOT state that they do not analyse blood 
samples. 
Table 1. Number and origin of participants completing the survey To deliver the survey, an electronic online survey 
tool was initially used (SurveyMonkey, San Mateo, 
USA). Before widespread dissemination across Eu-
ropean laboratories, the survey was piloted in Aus-
tria in 2016. Based on the results, the survey was 
reconfigured, and an alternate survey tool was fi-
nally used, which better fitted the aims of this pro-
ject (LimeSurvey, LimeSurvey GmbH, Hamburg, 
Germany). Some questions were shown to partici-
pants based on their answers to previous ques-
tions.
After approval by the EFLM Scientific Committee 
and the EFLM Executive Board, the survey was 
sent through the European Organisation for Exter-
nal Quality Assurance Providers in Laboratory 
Medicine (EQALM) network or EFLM national soci-
eties (when an EQALM organization was unavaila-
ble in the country) to members, with a request to 
further distribute the survey link, accompanied by 
an invitation letter to participating laboratories. 
Participants were asked to only fill in the online 
form once per laboratory between October 1st and 
November 30th, 2017. 
Evaluation of results was performed using IBM 
SPSS Statistics V.24 (IBM, Armonk, New York, USA). 
Answers from non-EFLM member countries were 
not incorporated in this evaluation. In country-
specific sub-analyses, countries with only five re-
spondents or less were also eliminated since these 
answers may not reflect the situation for the entire 
country. Content analysis on differences and simi-
larities within the text was used to analyse the 
written responses to the open-ended question: 
”Which preanalytical topics concern you the 
most?“ (10). According to the journals guideline, 
percentages are rounded and shown in whole 
numbers, except those < 10% if necessary and ap-
plicable (11). 
Results
Overall, 1416 participants from 45 countries com-
pleted the survey. Eleven of these responses were 
removed as they were provided by non-EFLM 
member countries, leaving 1405 responses from 
37 countries. Another 58 responders stated that 
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they were not involved in analysing blood sam-
ples. These participants were not introduced to 
the remaining questions. A list of the remaining 
1347 participants including the number of re-
sponses is shown in Table 1. A representative num-
ber of primary care laboratories as well as hospital 
laboratories, both privately owned and public, 
from a variety of analytical departments respond-
ed of which only 21% had no accreditation or certi-
fication status (Table 2).
Monitoring of preanalytical errors
Of the 1347 participants, 94% (N = 1265) stated 
they monitored/documented preanalytical errors. 
These results differed depending on the respond-
er’s home country (Figure 1). Reasons for not mon-
itoring preanalytical errors included the lack of hu-
man resources (6%; N = 5), technical issues (e.g., 
lack of specific software) (16%; N = 13), small labo-
ratory/sample size (6%; N = 5), no need and/or only 
few errors according to the laboratory (7%; N = 6), 
Overall
(N = 1347)
Not monitoring
preanalytical errors  
(N = 82)
N (%)* N (%)**
Please state if you work in a:
Primary Care Laboratory 250 (18) 22 (8.8)
Hospital laboratory 532 (38) 36 (6.8)
Laboratory that serves both primary care and hospital (in- and outpatients) 565 (40) 24 (4.2)
Please state the type of institution you work in
Privately owned (for-profit) laboratory 396 (28) 25 (6.3)
Public (non-profit) laboratory 951 (68) 57 (6.0)
What analytic department do you mainly work in?
General Clinical Chemistry 526 (37) 44 (8.4)
I work in many different analytic departments 338 (24) 16 (4.7)
Leading/Supervising position (e.g. head of department) 181 (13) 5 (2.8)
Haematology 67 (4.8) 2 (3.0)
Coagulation 13 (0.9) 1 (7.7)
Toxicology/TDM 6 (0.4) 1 (17)
Molecular Biology 12 (0.9) 0 (0)
Microbiology 77 (5.5) 7 (9.1)
Reception/Distribution of samples 8 (0.6) 0 (0)
POCT 8 (0.6) 4 (50)
Quality Management 58 (4.1) 1 (1.7)
Transfusion 5 (0.4) 0 (0)
Clinical Pathology 2 (0.1) 1 (50)
Endocrinology 7 (0.5) 0 (0)
Serology/Virology 2 (0.1) 0 (0)
Other 12 (0.9) 0 (0)
Immunology 22 (1.6) 0 (0)
No answer 3 (0.2) 0 (0)
Table 2. Basic data of participants including the number of laboratories not monitoring preanalytical errors
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Figure 1. European laboratories monitoring preanalytical errors. The number after the country name in brackets represent the total 
number of responses from this country. Responses from countries with less than 6 responses are not shown (Cyprus, Latvia, Lithu-
ania, Luxembourg, Poland, Romania, Ukraine).
Samples per day
< 500 628 (45) 56 (8.9)
500–3000 505 (36) 21 (4.2)
3001–10,000 177 (13) 5 (2.8)
> 10,000 37 (2.6) 0 (0)
Is your laboratory accredited, certified or similar? (Multiple answers possible)
ISO 15189 593 (44) 11 (1.9)
ISO 17025 68 (5.0) 5 (7.4)
ISO 9001 252 (19) 13 (5.2)
ISO 22870 18 (1.3) 1 (5.6)
National standard 232 (17) 17 (7.3)
Ongoing accreditation / certification 28 (2.1) 2 (7.1)
Other 29 (2.2) 0 (0.0)
No accreditation/certification 289 (21) 44 (15)
Answers only by responders who were from EFLM member countries and did NOT state that they do not analyse blood samples. 
*Percentage of total. **Percentage of the number of laboratories in the “overall” column. TDM – therapeutic drug monitoring. 
POCT - point of care testing.
along with other reasons (20%; N = 16). The an-
swer to this question was left blank by 45% (N = 
37) of responders. Nearly half of responders who 
were not monitoring preanalytical errors (46%; N = 
38) declared to be accredited or certified (Table 2, 
Supplemental table 2). Of those responders who 
monitored preanalytical errors, 16% (N = 202) used 
manual documentation of errors (e.g. Excel, hand-
written, or similar), without these being entered in 
the Laboratory Information System (LIS). Another 
37% (N = 475) entered errors directly into the LIS 
(either by manual input or automatically) and 43% 
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(N = 543) used a combination of manual and elec-
tronic documentation. The remaining 4% (N = 45) 
of responders did not document preanalytical er-
rors after identifying/measuring them. The results 
from haemolysis, icterus and lipemia measure-
ment, documentation and usage of the results are 
shown and discussed in the second manuscript 
(part 2) of this series (9). 
Further processing of preanalytical 
information
Of responders actually monitoring preanalytical 
errors, 31% (N = 390) stated they did not perform 
further evaluation of these data. Of the remaining 
875 laboratories, which did evaluate data from 
preanalytical errors either periodically or irregular-
ly, 24% (N = 207) stated that this evaluation was 
not accompanied by improvement actions and 
33% (N = 285) of responders claimed that no fol-
low-up processes were initiated when preanalyti-
cal values deteriorated or lay outside a defined 
threshold (Figure 2). Respective accreditation/cer-
tification status compared to these responses is 
shown in Supplemental table 2.
A total percentage of 93% (N = 1255) of responders 
analysing blood samples stated that they provided 
preanalytical guidance on laboratory parameters to 
the clinician/physician/sender either by online-da-
tabase (34%; N = 465), PDF-/EXCEL-list or a hard 
copy (10%; N = 141), both online and printed (32%; 
N = 425) or orally (e.g. upon inquiry or within educa-
tional training sessions) (17%; N = 224). Of respond-
ers not providing information to clinicians (7%; N = 
92), 24 stated to be accredited according to the ISO 
15189 guideline, which makes up 4% of all respec-
tive responders (Supplemental table 2). 
Figure 2. Use of preanalytical data
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Interest of participants in preanalytical issues 
and their willingness to actively engage in 
this topic 
When asked about the interest of laboratories in 
preanalytical topics/issues, 57% (N = 766) of re-
sponders stated that they would be interested in 
participating in an external quality assessment 
(EQA) program regarding preanalytical errors. An-
other 14% (N = 185) stated that they were already 
involved in similar programs. This interest varied 
between countries. In some, the majority would 
not be willing to participate, in others, the interest 
in preanalytical EQA programs was very high. 
Again in others, such EQA schemes were already in 
use. A detailed list of the interest in EQA participa-
tion sub-analysed by country is included in Sup-
plemental table 3. The interest of laboratories in 
participating in an EQA program compared to 
their accreditation/certification status, along with 
the types of laboratory, is shown in Table 3. 
The majority of responders stated to be interested 
in a preanalytical online platform (87%; N = 1177), 
a guideline for the measurement and evaluation 
of preanalytical variables (92%; N = 1235), and in 
preanalytical e-learning programs or webinars 
(84%; N = 1125). 
A total of 605 participants responded to the open-
ended question “Which preanalytical topics con-
cern you the most?” Results of the qualitative eval-
uation hereof showed that most text responses 
were comprehensive and could be categorized 
without division into meaningful units. The text 
response generated only three categories: stabili-
ty of analytes, analytical interference (HIL) and 
compliance to venous specimen collection guide-
lines. 
Stability of analytes was a concern described as 
specific analyte stability in samples before and af-
ter centrifugation in different test tubes, over time 
until analysis and the control of transport condi-
tions. Some responders asked for stability tables 
and others related stability issues to transporta-
tion media such as pneumatic tube transport and 
especially for haemostasis samples. An over-
whelming number of responders expressed con-
cerns on analytical interference (e.g. HIL) and pre-
analytical sample handling in order to avoid HIL 
occurrence as well as EFLM consensus on recom-
mended rejection criteria. The wish for education-
al programs on how to handle analytical interfer-
ence also included drugs and autoantibodies. Re-
sponders described concerns regarding compli-
ance to venous specimen collection guidelines 
where traceability of patient identity and samples 
was an expressed concern as well as various issues 
on correct sampling practices.
Discussion
As the preanalytical phase is the part most prone 
to errors throughout the total testing process, a 
close inspection and continuous evaluation of this 
phase is essential to produce high quality test re-
sults. Our survey shows that among the 1347 par-
ticipating European responders analysing blood 
samples, nearly all (94%) do monitor or document 
preanalytical errors. These findings are in line with 
the results of a survey on the use of extra-analyti-
cal phase quality indicators (QI) in which Plebani et 
al. found that 90% of surveyed laboratories meas-
ured at least one or more extra-analytical QIs/er-
rors (12). However, according to our findings there 
seems to be no standardized way of collecting and 
documenting these errors, as some responders 
preferred entering these data directly into their LIS 
or used a combination of manual and electronic 
documentation, while others documented these 
errors manually or not at all after identifying or 
measuring them. Many/most commercially availa-
ble LIS lack the preconfigured capability to docu-
ment quality indicators such as the amount of mis-
identified samples. Therefore, laboratories are 
forced to innovate with their own strategies. This 
is why those responders not monitoring preana-
lytical errors mentioned a lack of human resources 
or the LIS to support data collection as the two 
main reasons hereof. Survey results from Plebani 
et al. were similar to our findings, and led the au-
thors to define the term of the “quality indicator 
paradox”, a situation with increasing interest in 
collecting data on extra-analytical errors on one 
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Table 3. Interest of European laboratories in preanalytical topics/issues, depending on the type and size as well as on the accredita-
tion/certification status of the laboratory 
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side, but with only few laboratories making regu-
lar comprehensive data collections on the other 
(13). 
When analysing our findings more closely, there 
seems to be a clear link between monitoring pre-
analytical errors and the number of samples pro-
cessed per day by the laboratory. The number of 
responders not monitoring these errors decreases 
constantly from 8.9% to 0% with increasing num-
ber of samples processed per day. This also fits 
perfectly to some of the reasons these responders 
gave on why they chose not to focus on preana-
lytical issues such as “small laboratory/sample size” 
or “no need and/or only few errors according to 
the laboratory”. Overall, it seems that responders 
working in smaller laboratories tend to focus less 
on topics within the preanalytical phase compared 
to those employed in bigger facilities. One reason 
may be that the effort to establish and maintain a 
rigid quality management system for the extra-an-
alytical phase is similar for either size of laborato-
ries, both financially and in terms of human re-
sources. Another possible reason may be the lack 
of expertise in preanalytical error handling and 
documentation in small to very small laboratories. 
Another influencing source of variation on wheth-
er or not the preanalytical phase is being moni-
tored, is the country of origin of the response, 
ranging from a 100% to only 57% of responders in 
countries tracking errors (Figure 1). The reason is 
unclear but may be influenced by the national so-
ciety’s activities and local regulatory requirements.
A very interesting finding of this survey was the 
fact that nearly a third of responders who moni-
tored and documented preanalytical errors, did 
not evaluate these periodically. Moreover, of those 
who did, nearly a quarter took no action when 
preanalytical values worsened or were outside de-
fined ranges. Additionally, nearly half of the re-
sponders who monitored preanalytical errors 
lacked a standardized follow-up process when val-
ues worsened or were outside the defined ranges. 
Preanalytical errors may be measured and docu-
mented by means of reporting them to clinicians 
alongside the requested test result, thus allowing 
their accurate interpretation. This does not neces-
sarily mean that these measurements of preana-
lytical errors are being used for general statistical 
evaluation. However, only monitoring/document-
ing these errors without any action taken, based 
on the individual findings, is undoubtedly not im-
proving the total testing process. Errors like hae-
molysis rates need to be evaluated not only for 
specific laboratory reports, but also generally over 
time on a very detailed level. This enables labora-
tory professionals to contact the specific health 
care workers/wards/areas/locations needing at-
tention and to develop ways of improving the situ-
ation (14,15). Tools to approach the problem are 
freely available when documentation within a LIS 
is not possible (16-18).  
When providing analytical test results, each labo-
ratory should be concerned about all parts of the 
total testing process. The role of a medical labora-
tory is not only to provide test results at a reason-
able turnaround time, but also to aid clinicians in 
choosing the right test, with the right interpreta-
tion, and to help medical staff avoiding preanalyti-
cal errors in order to maintain high quality analyt-
ics (19-21). To do so, laboratories are encouraged, 
or even required, to provide information on the as-
say portfolio including preanalytical instructions 
to the clinician (22). The results of our survey show 
that nearly all responders across Europe (93%; N = 
1255) were following this recommendation in 
some way. Nevertheless, an online-platform with 
current information regarding preanalytical topics 
(e.g. analytical stability of parameters, preanalyti-
cal influences on individual parameters, guide-
lines, etc.), hosted and kept up-to-date by the 
EFLM, accessible for everyone, seems reasonable. 
Laboratories could then refer to this database in-
stead of needing to collect the respective informa-
tion locally. When asked, nearly 90% of responders 
would be in favour of such a database. Although 
different platforms dealing with laboratory param-
eters are already in place, their major concern is re-
lated to their use and interpretation (23). As there 
is currently no platform especially focusing on pa-
rameter-specific preanalytical conditions, the 
EFLM WG-PRE interprets the result of this question 
as a clear assignment to start building one. 
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In addition, the interest in a guideline for measure-
ment and evaluation of preanalytical variables was 
high. Indeed, such guidelines already exist. The In-
ternational Federation of Clinical Chemistry and 
Laboratory Medicine (IFCC) Working Group on 
“Laboratory errors and patient safety” (WG-LEPS) 
has established a model of quality indicators 
(MQI), providing instructions on collecting and 
documenting pre-analytical, analytical and post-
analytical QIs, also including the possibility to 
benchmark local QIs on a national and internation-
al level (24). Despite continuous efforts in advertis-
ing this freely accessible platform, only relatively 
few laboratories are aware of this possibility (12). 
To improve knowledge and awareness in preana-
lytical topics, the EFLM has recently re-launched a 
completely new and free e-learning platform, of-
fering live webinars and its recordings, along with 
e-learning courses on many different topics within 
the laboratory, including pre-analytical issues (25). 
This fits well to the results of the respective ques-
tion of our survey, where the vast majority of re-
sponders stated to be interested in such an educa-
tional database. 
In contrast, the interest in participating in an EQA 
program focusing on preanalytical topics was far 
lower. This finding differed by country. Some 
countries like Hungary, Croatia, UK, Ireland, Swe-
den, Norway and Spain had the highest amount of 
responders already participating in such EQA 
schemes, which may be linked with national socie-
ties or respective EQA providers. The low interest 
in many other countries might be due to the fact 
that the portfolios of EQA providers do not include 
preanalytical schemes. However, the number of 
respective EQA programs is increasing (26-31). 
Similar to the correlation between monitoring pre-
analytical errors and laboratory sizes, the interest 
in participating in a preanalytical EQA program 
was found to be positively correlated with the 
number of samples processed by respective re-
sponders. This confirms our hypothesis that big-
ger laboratories tend to acknowledge preanalyti-
cal issues more than small ones. 
Reviewing answers only from laboratories stating 
to be accredited according to the ISO 15189 guide-
line, the interest in a preanalytical online-informa-
tion-platform, in preanalytical guidelines, in e-
learning programs or webinars on preanalytical 
monitoring and best-practices and especially on 
EQA programs regarding preanalytical errors, were 
lower than one would expect from accredited lab-
oratories. The ISO 15189 guideline strives to im-
prove quality in laboratory testing by standardiz-
ing key processes throughout every laboratory 
(22). Although the demands within this document 
are quite clear, and some of them exclusively con-
cerned preanalytical processes, it seems that a cer-
tain amount of responders claiming to follow this 
guideline did not adhere to these demands. Al-
though 98% (N = 582) of these responders claim to 
monitor/document preanalytical errors in general, 
many of these do not evaluate these measure-
ments, or take any corrective action in terms of a 
continuous improvement process, and some do 
not provide preanalytical instructions to clinicians.
At the end of our survey, we asked an open ques-
tion on which preanalytical issue the responders 
were most concerned about. We found that most 
responders were concerned about analytical inter-
ference and avoidance HIL as well as recommend-
ed rejection criteria. Much has been published on 
interference of HIL on laboratory tests including a 
CLSI guideline on interference testing (32-36). Due 
to the heterogeneity of manufacturers’ declara-
tions on these interferences, this topic still is a pro-
found concern in many laboratories (5,37). This is 
why the WG-PRE has lately called for more trans-
parency in these declarations (38). Additionally, 
the WG-PRE has published recommendations on 
reporting and managing haemolysed samples 
(39,40). 
Another major concern of European responders 
entails data on analyte stability in different sam-
ples types and temperatures. This topic is also be-
ing addressed by the WG-PRE, partly by providing 
available data in an easily accessible format and 
partly by providing consensus on how to retrieve 
respective data in a standardized way.  
A third category of requests from surveyed labora-
tories regarding compliance to venous specimen 
collection guidelines has already been fulfilled. 
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The WG-PRE has recently published a joint EFLM-
COLABIOCLI (Latin America Confederation of Clini-
cal Biochemistry) recommendation for venous 
blood sampling which is freely available, and in-
cludes extensive additional tools, making it possi-
ble for health care facilities to easily standardize 
the phlebotomy process (41). 
As limiting factors, we have to mention that al-
though we advised responders to give only one 
answer per laboratory, we cannot rule out that 
more than one answer was given by the same lab-
oratory. Due to data protection regulations, we re-
frained from collecting the exact IP addresses of 
responders. Additionally, we are aware that some 
countries are overrepresented (e.g. France, Spain) 
while other might be underrepresented. This is at 
least in part due to differences in the number of 
laboratories per country. We dealt with this issue 
by providing country-specific evaluation wherever 
appropriate.  
In conclusion, we show that monitoring the prean-
alytical phase of the total testing process and act-
ing upon these data varies largely throughout Eu-
rope. The interest in preanalytical issues is pleas-
antly high. With the findings of this survey, the 
WG-PRE now has confirmation that its members 
are heading in the right direction with all of the 
current and planned projects, aiming to harmo-
nize/standardize the preanalytical phase in Eu-
rope.
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